NEW YORK (GenomeWeb News) - Third Wave Technologies said today that it will collaborate with Laboratory Corporation of America to develop a diagnostic that may be used in conjunction with a heart failure drug that is being developed by Arca Discovery. 
 
The diagnostic is intended to help physicians determine use of the drug bucindolol, a beta blocker that Third Wave said could be "the first genetically targeted cardiovascular drug."
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.